Amal Therapeutics Exit

Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic cargo.

Press releases

12. November 2018
AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round
Second closing of Series B raises €21.2 million (CHF 24.2 million) Funding to support clinical development of lead vaccine and extension of KISIMA® technology platform Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund with VI Partners, Schroder Adveq and High-Tech Gründerfonds also participating AMAL Therapeutics SA (AMAL), a Swiss biotech developing peptide-based therapeutic cancer vaccines, today announces that it has completed
30. March 2016
Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund
Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccines. The company will use the funds to progress the preclinical development of its lead vaccine (ATP124) for color
20. February 2014
Amal Therapeutics SA raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds to develop therapeutic cancer vaccines based on its proprietary technology platform
Amal Therapeutics SA, a Geneva and Berlin-based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-penetrating peptide based technology platform and progress the first vaccine candidate up to pre-clinical development. The investment round was led by Boehringer Ingelheim Venture Fund (BIVF), joined by High-Tech Gründerfonds (HTGF). The company also announced that it appoin

Info & Contact


Avenue de la Roseraie 64
1205 Geneva

In portfolio

07. Feb 2014 – 28. Jun 2019


HTGF Manager

Dr. Frank Hensel, Principal / Authorized signatory